David Dornan - 15 Feb 2024 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELEV	Stock Option (Right to Buy)	Award	$0	+225,000		$0.000000	225,000	15 Feb 2024	Common Stock	225,000	$2.77	Direct	F1
transaction	ELEV	Restricted Stock Unit	Award	$0	+37,500		$0.000000	37,500	15 Feb 2024	Common Stock	37,500		Direct	F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The stock option vests as to 25% of the total shares on February 15, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F2	Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F3	25% of the RSUs vest on February 15, 2025, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F4	The RSUs do not expire; they either vest or are canceled prior to the vesting date.